Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Volcano Corporation highlight its new product launches  presence in live cases, and participation in late breaking trials during EuroPCR.

Volcano Corporation announced the company's plans to highlight its new product launches, presence in live cases, and participation in late breaking trials during EuroPCR from May 25 - 28 in Paris.

"Through both imaging and therapy, Volcano continues to lead the way in providing innovative solutions to best meet the complex needs of the interventional vascular physician and their patients," said Michel Lussier, Group President for Advanced Imaging Systems, Scientific Affairs, and Volcano Europe, Africa, and the Middle East ( EAME ). "We look forward to furthering the most progressive year of internally-developed technological innovations our company has seen yet that address the limitations of angiography. Not only do we continue to launch new-to-the-world technologies, we are also pleased to further optimize already commercialized intravascular ultrasound ( IVUS ) and fractional flow reserve ( FFR ) products to make some of our best products even better."

Product Innovations

During EuroPCR, Volcano will showcase its new CE Mark approved additions to its suite of integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. The new product introductions from Volcano are:

- Eagle Eye Platinum, an optimization of the #1 digital IVUS catheter,

designed for improved deliverability with the convenience of radiopaque

markers;

- PrimeWire PRESTIGE, the next generation FFR wire with enhanced

torque response, vessel navigation and support for treating

multi-vessel disease patients; and

- The s5(TM)/s5i 3.2 software, which streamlines the workflow for

both IVUS and FFR procedures and is compatible with more than 3,000

Volcano systems installed worldwide.

Volcano will also highlight its extensive pipeline of imaging and therapy products including the VIBE RX Vascular Imaging Balloon Catheter (which is awaiting CE Mark approval), Optical Coherence Tomography ( OCT ), and Forward Looking Imaging. All products will be available for demonstration at Booth #M07, Level 2. Volcano's IVUS and FFR technologies will also be highlighted in its partners' booths, including those of GE, Philips, and Siemens.

Volcano and Siemens will demonstrate continued development efforts to bring imaging co-registration to interventional cardiology. This technology will allow physicians to see their angiographic roadmap images linked side-by-side with the corresponding IVUS images in the cath lab. "Now, a patient's medical record will be even more complete," said Dave Sheehan, President of Volcano's IVUS and Physiology Businesses and Volcano Japan. "Plus, physicians will now have an additional layer of real-time precision to aid their strategic decision-making about how to best treat their patients." Volcano and Siemens plan to demonstrate the co-registration application from a live case in Erasmus University Medical Center in Rotterdam, the Netherlands.

Live Case Transmissions

Throughout EuroPCR, Volcano technology, including FFR, IVUS, and Image Co-Registration, will be featured in live case transmissions from around the world.

Clinical Trial Updates

Volcano's proprietary VH IVUS technology will be highlighted in two Late Breaking Data presentations (Times are Central European Time; events are at the Palais Des Congres De Paris):

VICTORY (VH In Carotids Observational Registry) is a European, multi-center prospective registry for carotid plaque characterization by VH IVUS during carotid stenting. Data on VICTORY will be presented at approximately 1:30 PM CET on Tuesday, May 25th, in Theatre Havane.

HEAVEN (Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration) is a Czech, prospective, randomized, multicenter controlled study that uses VH IVUS to measure the changes of plaque volume and the changes of plaque composition during atorvastatin and ezetimibe administration to the patient with stable angina. Data on HEAVEN will be presented at 8:48 AM CET on Thursday, May 27th, in Room Vendome.

Source: Volcano Corporations